By 2023, 60 million euros will flow into the production facility in Graz and the packaging center in Werndorf.
The global health care company Fresenius Kabi, which belongs to the German medical and hospital group Fresenius, is investing more than 60 million euros in the two Styrian locations in Graz-Puntigam and Werndorf by 2023, as the company announced on Wednesday evening. The German parent company is also a co-owner of the Austrian healthcare provider Vamed.
According to the Austrian subsidiary Fresenius Kabi Austria GmbH, the money will be used to expand production capacities and infrastructure in the Graz-Puntigam production facility and in the packaging center in Werndorf.
The expansion of the packaging center in Werndorf is already in full swing. The attached hall should be ready by this summer – “just in time for the new packaging and sifting systems”. The groundbreaking for the extension took place last Friday. At the Graz location, the expansion of the mobile preparation area, the expansion of the freeze drying (lyophilization) and the implementation of the new filling systems are ongoing.
Major investments were made in 2020 with the purchase of the logistics and packaging center in Werndorf. The focus is on freeze drying and systems for filling and packaging glass bottles and pre-filled syringes. “For us, pre-filled syringes are a rapidly growing market. Many healthcare facilities recognize the clear advantages in the fast and, above all, safe application,” said plant manager Ruth Staubmann in a press release.
In Graz, Fresenius Kabi manufactures liquid pharmaceuticals and products for clinical nutrition for the Austrian and international pharmaceutical market. According to the company, the strengths of the location include above all the know-how in aseptic production and the manufacture of complex products such as anesthetics, analgesics, anti-infectives and antibiotics.
“The fact that we have a broad field of activity and are not only dependent on a few customers and products helps Fresenius Kabi and we can therefore continue to look to the future with cautious optimism”, said Austria Managing Director Heinz Riesner.
In addition to the plant in Graz-Puntigam and the packaging and logistics center in Werndorf, Fresenius Kabi also operates a research and development center in Grambach (near Graz) and a production and sales location in Linz that specializes in the manufacture of active ingredients and lactulose. The company currently has around 1,500 employees – over 900 in the Graz plant.